Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Q4 2025 Annual earnings

Reported March 3, 2026 · After market close

Revenue$13.7MBeat by $5.2M
EPS-$0.01Beat by $0.12
Revenue estimate$8.5M
EPS estimate-$0.13

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q4 2025

Income statement

See full
Revenue$13.7M+31.1%
Gross profit$11.4M+35.2%
Operating income-$1.4M+25.6%
Net income-$1.4M+25.8%
EPS (diluted)-$0.09+35.7%

Balance sheet

See full
Cash & equivalents$11.4M-36.3%
Total debt$4.9M-52.5%
Total equity$24.9M+8.9%
Total assets$76.8M+1.6%

Cash flow

See full
Operating cash flow$3.0K—
CapEx--100%
Free cash flow$3.0K—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$59.53M+78.9%
Enterprise value$53.02M+106%
P/S1.3×+0.5×

Profitability

See full
Gross margin85%+2.4pp
Operating margin-6.3%-2.4pp
Net margin-6.4%-2.5pp
FCF margin10.9%—

Returns & leverage

See full
Return on equity-11.9%-4.1pp
Debt / equity0.2×-0.3×
Current ratio1×-0.1×

Segments

By product

See full
Sancuso$3.3M+38.2%
Kristalose$3.1M-28.7%
Vibativ$2.8M+35.4%
Caldolor$896.7K-34.7%
Other revenue$184.6K-14.9%

By geography

See full
Non-US$1.2M+81.5%

Versus estimates

Revenue

Q1 2026$9.1MBeat by $628.3K
Q4 2025$13.7MBeat by $5.2M
Q3 2025$8.3MQ2 2025$10.8MQ1 2025$11.7MQ4 2024$10.4M

Diluted EPS

Q1 2026-$0.13In line
Q4 2025-$0.01Beat by $0.12
Q3 2025-$0.06Q2 2025$0.02Q1 2025$0.16Q4 2024-$0.02

Ask the moment Cumberland Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cumberland Pharmaceuticals report Q4 2025 earnings?
Cumberland Pharmaceuticals (CPIX) reported Q4 2025 earnings on March 3, 2026 after market close.
What were Cumberland Pharmaceuticals's Q4 2025 revenue and EPS?
Cumberland Pharmaceuticals reported revenue of $13.7M and eps of $-0.01 for Q4 2025.
Did Cumberland Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $8.5M by $5.2M. EPS beat the consensus estimate of $-0.13 by $0.12.
How did Cumberland Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 31.1% from $10.4M a year earlier and eps grew 50.0% from $-0.02.
Where can I find Cumberland Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001087294-26-000015) and the 10-K periodic report (0001087294-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.